glp-1 surgery With Even More Powerful GLP-1s on the Horizon, Plastic Surgeons Are Upping the Body Contouring Game for Ozempic Patients Metabolic surgery and GLP-1 agonists

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031

However, some types of eating disorders could worsen with GLP1-RA and require monitoring and treatment by registered dietitian and/or behavioral health providers who specialize in eating disorders, with appropriate referrals to higher levels of care for disordered eating.

Overlooked research reveals a simple, cheap fix almost ignored.

GLP1 drugs like Ozempic and Wegovy are transforming obesity and diabetes care

Scott Harris, M.D., will be discussing the promise of #GLP1/#Glucagon approaches in treating #MASH and #MASLD, as well as the importance of developing therapies tailored to the specific needs of patients with #obesity and/or #MASH

Mechanism of Action: Triple vs Dual Agonis Feature Tirzepatide Retatrutide GLP-1 Activation Appetite & insulin Appetite & insulin GIP Activation Fat metabolism Fat []